More tools:Markets·Screener·Research·Chat

Nektar Therapeutics (NKTR) Financial Statements

Nektar Therapeutics
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S7RDK1
XNAS · usd
75.44▲ 1.25 (1.68%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close74.19
Day's Range74.00 – 77.76
52-Week Range33.40 – 109.00
Volume846.1K
Avg Volume576.2K
Share Statistics
Shares Outstanding
Employees63
ExchangeXNAS
Listed1994-05-03
Share count as of August 7, 2026
Loading Income Statement…
Key questions about Nektar Therapeutics (NKTR)
What is Nektar Therapeutics's Market Cap?
Nektar Therapeutics's Market Cap is $2.6B, based on as-reported figures from SEC (XBRL) filings.
What is Nektar Therapeutics's Enterprise Value?
Nektar Therapeutics's Enterprise Value is $2.5B, based on as-reported figures from SEC (XBRL) filings.
What is Nektar Therapeutics's Price / Sales?
Nektar Therapeutics's Price / Sales is 47.2×, based on as-reported figures from SEC (XBRL) filings.
What is Nektar Therapeutics's EV / Revenue?
Nektar Therapeutics's EV / Revenue is 46.5×, based on as-reported figures from SEC (XBRL) filings.
What is Nektar Therapeutics's EV / EBITDA?
Nektar Therapeutics's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Nektar Therapeutics's Revenue (TTM)?
Nektar Therapeutics's Revenue (TTM) is $54.6M, based on as-reported figures from SEC (XBRL) filings.
What is Nektar Therapeutics's Net Income (TTM)?
Nektar Therapeutics's Net Income (TTM) is -$157.1M, based on as-reported figures from SEC (XBRL) filings.
What is Nektar Therapeutics's EBITDA?
Nektar Therapeutics's EBITDA is -$140.0M, based on as-reported figures from SEC (XBRL) filings.
What is Nektar Therapeutics's Diluted EPS (TTM)?
Nektar Therapeutics's Diluted EPS (TTM) is -4.60, based on as-reported figures from SEC (XBRL) filings.
What is Nektar Therapeutics's EBITDA Margin?
Nektar Therapeutics's EBITDA Margin is -256.5%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue
YoY growth-9.3%+3.8%-25.3%-51.1%
Operating costs and expenses:
Research and development (including $1,137 and $613 for the three months ended June 30, 2026 and 2025, respectively, from a related party; and $2,845 and $821 for the six months ended June 30, 2026 and 2025, respectively, from a related party)
General and administrative
Restructuring and impairment
Total operating costs and expenses
% of revenue517.9%459.6%226.9%368.6%
Loss from operations
% of revenue-417.9%-359.6%-126.9%-268.6%
Non-operating income (expense):
Non-cash interest expense on liabilities related to the sales of future royalties
Interest income
Other income (expense), net (including income of $0 and $540 for the three months ended June 30, 2026 and 2025, respectively, from a related party; and income of $2 and $861 for the six months ended June 30, 2026 and 2025, respectively, from a related party)
Total non-operating income (expense), net
Loss before provision (benefit) for income taxes and equity method investment
Provision (benefit) for income taxes
Loss before equity method investment
Loss from equity method investment
Net loss
% of revenue-401.0%-413.4%-165.4%-301.3%
Basic net loss per share (in dollars per share)
Diluted net loss per share (in dollars per share)